Printer Friendly

CEL-SCI CORPORATION'S TECHNOLOGY PROTECTED BY TWO MORE PATENTS

 CEL-SCI CORPORATION'S TECHNOLOGY PROTECTED BY TWO MORE PATENTS
 ALEXANDRIA, Va., April 10 /PRNewswire/ -- CEL-SCI Corporation (NASDAQ: CELI) announced today that it now holds the exclusive worldwide license to recently issued European Patent No. 0136375 and U.S. Patent No. 5,093,479. These two patents cover the production of a serum-free and mitogen-free Interleukin-1 (IL-1) preparation by culturing human peripheral mononuclear blood cells.
 CEL-SCI President Maximilian de Clara said: "These new patents significantly strengthen the company's protection for its technology. At this point, it should be fairly apparent to anybody that the value of a promising drug is determined significantly by the marketing rights and patent rights."
 CEL-SCI Corporation has long been an advocate of natural cell-culture for the production of complex human proteins such as the lymphokines and cytokines because it believes that the body's immune system is sophisticated enough to determine the difference between a natural and an artificial copy of a human protein.
 The human clinical trials using BC-IL, a product consisting of a mixture of human lymphokines, have shown that the product is so well tolerated that it can be administered to terminal cancer patients on an out-patient basis. Early results with a small number of terminal head and neck cancer patients have been promising.
 -0- 4/10/92
 /CONTACT: Daryll Strahl for CEL-SCI, 303-979-5735/
 (CELI) CO: CEL-SCI Corporation ST: Virginia IN: MTC SU:


DC-SB -- DC014 -- 7146 04/10/92 10:35 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 10, 1992
Words:237
Previous Article:LOS ANGELES AREA CONSUMER PRICES UP 0.4 PERCENT IN MARCH, FOOD AND BEVERAGES CITED
Next Article:DU PONT HONORS 100 EMPLOYEES FOR MARKETING ACHIEVEMENTS


Related Articles
CEL-SCI CORPORATION NAMES TWO OUTSIDERS TO ITS BOARD OF DIRECTORS
CEL-SCI WINS FINAL ROUND IN EUROPEAN PATENT LITIGATION
CEL-SCI WINS FINAL ROUND IN EUROPEAN PATENT LITIGATION
CEL-SCI CORPORATION ANNOUNCES ESTABLISHMENT OF PRODUCTION FACILITY
CEL-SCI CORPORATION TECHNOLOGY PROTECTED BY NEW JAPANESE PATENT
CEL-SCI ENTERS INTO AGREEMENT TO GAIN 100% OWNERSHIP OF AIDS TECHNOLOGY
CEL-SCI CORPORATION FILES CONTRACT BREACH AND PATENT INFRINGEMENT LAWSUITAGAINST IMMUNORX AND DR. JOHN HADDEN, A FORMER COLLABORATOR
CEL-SCI CORPORATION TO PRESENT PROMISING TUBERCULOSIS RESULTS IN MAY
CEL-SCI CORPORATION PRESENTS PROMISING DATA IN ITS QUEST FOR A TUBERCULOSIS VACCINE
KEY PRODUCT PATENT FOR CEL-SCI ALLOWED BY JAPANESE PATENT OFFICE

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters